INMB - NASDAQ

INmune Bio, Inc.

INMB·NASDAQ

$1.89

-1.3%

HealthcareBiotechnology

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.25M

EPS-2.1100

P/E Ratio-2.21

Earnings Date03/26/2026

39.56M

Assets

-31%

3Y-60.0%

5Y+62.0%

10Y+332857.0%

7.46M

Total Liabilities

-60%

3Y-62.0%

5Y+767.0%

10Y+24176.0%

32.10M

Total Equity

-16%

3Y-60.0%

5Y+36.0%

10Y-170213.0%

INmune Bio, Inc. Funding & Solvency Profile

INMB · NASDAQ

Current Assets

Cash & Cash Equivalents20.92M

Net Receivables1.41M

Inventory0.00

Other Current Assets331.00K

Total Current Assets23 M

Non-Current Assets

Property, Plant & Equipment307.00K

Goodwill & Intangible Assets16.51M

Long-Term Investments0.00

Other Non-Current Assets79.00K

Total Non-Current Assets386 K

Total Assets

39.56M

Financial Health Analysis

Current Ratio

3.14x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.23x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

15 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

57% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

INmune Bio, Inc. Balance Sheet

INMB • NASDAQ

INmune Bio, Inc. Balance Sheet	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	20.9M	35.8M	52.2M	74.8M	22M	7M	186.2K	1.4M	141.7K	11.9K
Cash & Short-Term Investments	20.9M	35.8M	52.2M	74.8M	22M	7M	186.2K	1.4M	141.7K	11.9K
Net Receivables	1.4M	2.4M	8.5M	5.5M	0.0	645.4K	647.6K	327.6K	0.0	0.0
Accounts Receivables	1.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	2.4M	8.5M	5.5M	0.0	645.4K	18K	109.1K	0.0	0.0
Inventory	0.0	0.0	34K	-5.5M	0.0	-769.1M	0.0	0.0	0.0	0.0
Prepaids	0.0	1.7M	4.1M	2.3M	220K	123.9K	15.6K	42.6K	3K	0.0
Other Current Assets	331K	0.0	-34K	5.5M	1.8M	769.1M	0.0	0.0	306.9K	0.0
Total Current Assets	22.7M	39.9M	64.7M	82.6M	24M	7.8M	849.3K	1.9M	451.6K	11.9K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	307K	414K	507K	726K	156K	191.5K	0.0	0.0	0.0	0.0
Intangible Assets	16.5M	16.5M	16.5M	16.5M	16.5M	16.5M	16.5M	16.5M	0.0	0.0
Goodwill & Intangible Assets	16.5M	16.5M	16.5M	16.5M	16.5M	16.5M	16.5M	16.5M	0.0	0.0
Other Non-Current Assets	79K	131K	99K	99K	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Assets	16.9M	17.1M	17.1M	17.3M	16.7M	16.7M	16.5M	16.5M	0.0	0.0
Total Assets	39.6M	57M	81.8M	99.9M	40.7M	24.5M	17.4M	18.4M	451.6K	11.9K
LIABILITIES
CURRENT LIABILITIES
Total Payables	6.6M	7.9M	5.2M	3.8M	1.5M	402K	553.2K	136.4K	220.8K	750.0
Accounts Payable	6.6M	7.9M	5.2M	3.8M	1.5M	402K	553.2K	136.4K	220.8K	750.0
Accrued Expenses	0.0	0.0	0.0	0.0	34K	290.1K	270.5K	173.3K	0.0	0.0
Short Term Debt	0.0	9.9M	5M	72K	0.0	0.0	0.0	0.0	350K	0.0
Capital Lease Obligations (Current)	140K	119K	87K	72K	34K	8.3K	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	616K	474K	0.0	-298.4K	0.0	0.0	0.0	0.0
Other Current Liabilities	517K	524K	9K	-62K	190K	298.4K	0.0	0.0	30K	30K
Total Current Liabilities	7.2M	18.5M	10.9M	4.4M	1.8M	700.4K	823.8K	309.7K	600.8K	30.8K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	9.7M	14.5M	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	550K	199K	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	244K	397K	10.8M	15.4M	126K	160.2K	0.0	0.0	0.0	0.0
Capital Lease Obligations	384K	516K	613K	776K	160K	168.5K	0.0	0.0	0.0	0.0
Total Liabilities	7.5M	18.9M	21.7M	19.7M	1.9M	860.5K	823.8K	309.7K	600.8K	30.8K
SHAREHOLDERS' EQUITY
Common Stock	22K	817K	18K	18K	13K	10.8K	8.7K	8.3K	5.1K	5K
Additional Paid-In Capital	195.8M	159.1M	151.8M	143.9M	72.1M	44.8M	25.4M	19.2M	124.9K	25K
Retained Earnings	-163.1M	-121M	-91M	-63.7M	-33.4M	-21.3M	-13.6M	-1.2M	-326.4K	-48.9K
Accumulated Other Comprehensive Income/Loss	-575K	-799K	-699K	1K	11K	-8.5K	6.5K	32K	47.2K	0.0
Total Stockholders' Equity	32.1M	38.1M	60.1M	80.2M	38.8M	23.6M	16.5M	18.1M	-149.2K	-18.9K
Total Equity	32.1M	38.1M	60.1M	80.2M	38.8M	23.6M	16.5M	18.1M	-149.2K	-18.9K
SUMMARY
Total Liabilities & Equity	39.6M	57M	81.8M	99.9M	40.7M	24.5M	17.4M	18.4M	451.6K	11.9K
Total Debt	384K	10.4M	15.3M	15.2M	160K	168.5K	0.0	0.0	350K	0.0
Net Debt	-20.5M	-25.4M	-36.8M	-59.6M	-21.8M	-6.8M	-186.2K	-1.4M	208.3K	-11.9K
Shares Outstanding	26,585,258	26,585,258	26,585,258	26,585,258	26,585,258	26,585,258	26,585,258	26,585,258	26,585,258	26,585,258

SEC Filings

INMB - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2025 N/A	December 19, 2025	December 19, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 10, 2025	December 05, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 08, 2025	December 05, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 05, 2025	December 01, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 03, 2025	December 02, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 28, 2025	November 26, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 18, 2025	November 18, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 10, 2025	November 10, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 30, 2025	October 30, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	October 30, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 323 filings

Related Guides

Blog Categories

Continue your INMB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.